Clinical research
The co-primary endpoints were pain freedom and freedom from the symptom that bothers the patient the most at two hours after receiving the drug. The trial hit its co-primary endpoints.
Companies from across Europe, Asia and around the globe share pipeline and business updates.
The two-drug combination of Dovato provided similar long-term viral suppression to common three-drug regimens.
NANOBIOTIX announced that the previously reported results from the Phase II/III Act.In.Sarc trial evaluating NBTXR3 in patients with advanced STS have been published online in The Lancet Oncology.
Medical Research Council (MRC) Grants Funding for Bermekimab as Part of its Support for “Outstanding Clinical Programs in the United Kingdom”
Engage Therapeutics, Inc. announced that data from a phase 2a study of Staccato® alprazolam to suppress seizures in patients with epilepsy were published in the peer-review journal Epilepsia.
Placebo-controlled, multi-center trial will evaluate safety, tolerability and efficacy biomarkers to assess potential best-in-class FXR agonist
Cara Therapeutics, Inc. announced the initiation of a Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with atopic dermatitis.
SonoCloud ultrasound device for glioblastoma patients will be tested for first time at US clinical sites
Karolinska Development’s portfolio company Dilafor AB, a drug development company focusing on the development of tafoxiparin for obstetric indications, has enrolled the first subject in its Phase 2b study with tafoxiparin in pregnant women planned for labor induction.
PRESS RELEASES